ID
22015
Beskrivning
Study part: Protocol exceptions. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"
Nyckelord
Versioner (1)
- 2017-05-14 2017-05-14 -
Rättsinnehavare
Roche
Uppladdad den
14 maj 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
PROTOCOL EXCEPTIONS Roche H0650g Breast Cancer
PROTOCOL EXCEPTIONS
- StudyEvent: ODM
Beskrivning
2. IF YES. PLEASE INDICATE THE NUMBER(S) OF ELIGIBILITY CRITERIA FROM THE WORKSHEET WHICH WERE NOT SATISFIED AND PROVIDE A BRIEF DESCRIPTION OF EACH. PL.EASE ALSO SPECIFY THE NAME OF THE EMPLOYEE CONTACTED FOR APPROVAL AND THE DATE APPROVAL WAS OBTAINED
Beskrivning
Eligibility Criteria
Datatyp
text
Alias
- UMLS CUI [1]
- C1516637
Beskrivning
description Eligibility Criteria
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0678257
- UMLS CUI [1,2]
- C1516637
Beskrivning
investigator name
Datatyp
text
Alias
- UMLS CUI [1]
- C2826892
Beskrivning
DATE OF CONTACT
Datatyp
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0332158
Beskrivning
Investigator name
Datatyp
text
Alias
- UMLS CUI [1]
- C2826892
Similar models
PROTOCOL EXCEPTIONS
- StudyEvent: ODM
C0545082 (UMLS CUI [1,2])
C1516637 (UMLS CUI [1,2])
C0332158 (UMLS CUI [1,2])